Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma
Despite high prevalence, urinary incontinence is still very much a taboo
20 September 2021New method used to study how cancer cells are organised
20 September 2021Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma
The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo. The late breaking results of the KEYNOTE-716 trial are presented at the ESMO Congress 2021.
